StageZero Life Sciences Ltd. (SZLSF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 | -7.74 Million USD | 4.72% |
| 2021 | -8.13 Million USD | -119.81% |
| 2020 | -3.69 Million USD | 27.65% |
| 2019 | -5.11 Million USD | -17.4% |
| 2018 | -4.35 Million USD | -11.77% |
| 2017 | -3.89 Million USD | 8.63% |
| 2016 | -4.26 Million USD | 29.44% |
| 2015 | -6.04 Million USD | 8.6% |
| 2014 | -6.61 Million USD | 7.11% |
| 2013 | -7.11 Million USD | -62.6% |
| 2012 | -4.37 Million USD | -17.78% |
| 2011 | -3.71 Million USD | 12.54% |
| 2010 | -4.25 Million USD | 13.3% |
| 2009 | -4.9 Million USD | 55.89% |
| 2008 | -11.11 Million USD | -6.74% |
| 2007 | -10.41 Million USD | -30.56% |
| 2006 | -7.97 Million USD | -187.95% |
| 2005 | -2.76 Million USD | 41.36% |
| 2004 | -4.72 Million USD | -1306.04% |
| 2003 | -335.9 Thousand USD | 61.9% |
| 2002 | -881.57 Thousand USD | 30.04% |
| 2001 | -1.26 Million USD | -410.72% |
| 2000 | -246.73 Thousand USD | -717.61% |
| 1999 | 39.94 Thousand USD | 687.31% |
| 1998 | -6802.08 USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -314.77 Thousand USD | 0.0% |
| 2024 Q2 | -695.28 Thousand USD | -120.88% |
| 2023 Q3 | -760.73 Thousand USD | 7.31% |
| 2023 Q1 | -1.28 Million USD | 24.82% |
| 2023 Q2 | -820.75 Thousand USD | 36.25% |
| 2022 Q1 | -2.63 Million USD | 14.16% |
| 2022 Q3 | -1.45 Million USD | 27.68% |
| 2022 Q2 | -2 Million USD | 23.96% |
| 2022 FY | -7.74 Million USD | 4.72% |
| 2022 Q4 | -1.71 Million USD | -18.04% |
| 2021 Q1 | -1.7 Million USD | -142.7% |
| 2021 Q3 | -2.49 Million USD | -6.51% |
| 2021 Q4 | -3.07 Million USD | -23.33% |
| 2021 Q2 | -2.33 Million USD | -37.51% |
| 2021 FY | -8.13 Million USD | -119.81% |
| 2020 Q3 | -572.77 Thousand USD | 52.08% |
| 2020 Q4 | -700.99 Thousand USD | -22.39% |
| 2020 FY | -3.69 Million USD | 27.65% |
| 2020 Q1 | -909.08 Thousand USD | 26.34% |
| 2020 Q2 | -1.19 Million USD | -31.47% |
| 2019 FY | -5.11 Million USD | -17.4% |
| 2019 Q1 | -1.23 Million USD | -647.25% |
| 2019 Q4 | -1.23 Million USD | 3.26% |
| 2019 Q3 | -1.27 Million USD | 6.96% |
| 2019 Q2 | -1.37 Million USD | -11.32% |
| 2018 Q4 | -164.84 Thousand USD | 85.5% |
| 2018 FY | -4.35 Million USD | -11.77% |
| 2018 Q1 | -1.13 Million USD | -775.18% |
| 2018 Q2 | -1.75 Million USD | -55.1% |
| 2018 Q3 | -1.13 Million USD | 35.15% |
| 2017 Q1 | -1.23 Million USD | -140.29% |
| 2017 FY | -3.89 Million USD | 8.63% |
| 2017 Q3 | -1.16 Million USD | 23.43% |
| 2017 Q4 | 167.38 Thousand USD | 114.33% |
| 2017 Q2 | -1.52 Million USD | -23.64% |
| 2016 FY | -4.26 Million USD | 29.44% |
| 2016 Q1 | -740.47 Thousand USD | 53.81% |
| 2016 Q4 | -513.53 Thousand USD | 70.09% |
| 2016 Q3 | -1.71 Million USD | -32.74% |
| 2016 Q2 | -1.29 Million USD | -74.69% |
| 2015 Q1 | -958.71 Thousand USD | 81.7% |
| 2015 Q2 | -1.27 Million USD | -33.33% |
| 2015 Q3 | -2.17 Million USD | -70.04% |
| 2015 FY | -6.04 Million USD | 8.6% |
| 2015 Q4 | -1.6 Million USD | 26.24% |
| 2014 FY | -6.61 Million USD | 7.11% |
| 2014 Q4 | -5.23 Million USD | -554.63% |
| 2014 Q3 | -800.41 Thousand USD | 2.3% |
| 2014 Q2 | -819.28 Thousand USD | 49.6% |
| 2014 Q1 | -1.62 Million USD | -20.44% |
| 2013 FY | -7.11 Million USD | -62.6% |
| 2013 Q4 | -1.34 Million USD | 51.87% |
| 2013 Q3 | -2.8 Million USD | -71.61% |
| 2013 Q2 | -1.63 Million USD | -24.11% |
| 2013 Q1 | -1.31 Million USD | -51.45% |
| 2012 Q2 | -1.09 Million USD | 0.56% |
| 2012 Q4 | -869.35 Thousand USD | 31.42% |
| 2012 Q1 | -1.09 Million USD | 1.42% |
| 2012 Q3 | -1.26 Million USD | -16.1% |
| 2012 FY | -4.37 Million USD | -17.78% |
| 2011 FY | -3.71 Million USD | 12.54% |
| 2011 Q1 | -981.38 Thousand USD | -1.72% |
| 2011 Q2 | -938.25 Thousand USD | 4.4% |
| 2011 Q3 | -3.06 Million USD | -226.36% |
| 2011 Q4 | -1.11 Million USD | 63.63% |
| 2010 Q3 | -905.17 Thousand USD | 17.51% |
| 2010 Q4 | -964.8 Thousand USD | -6.59% |
| 2010 Q2 | -1.09 Million USD | 13.92% |
| 2010 Q1 | -1.27 Million USD | -1961.09% |
| 2010 FY | -4.25 Million USD | 13.3% |
| 2009 Q4 | 68.49 Thousand USD | 105.72% |
| 2009 Q2 | -1.4 Million USD | 5.07% |
| 2009 Q1 | -1.47 Million USD | -34.45% |
| 2009 Q3 | -1.19 Million USD | 14.54% |
| 2009 FY | -4.9 Million USD | 55.89% |
| 2008 Q4 | -1.09 Million USD | 70.38% |
| 2008 Q1 | -2.58 Million USD | 56.02% |
| 2008 Q2 | -3.95 Million USD | -53.22% |
| 2008 Q3 | -3.7 Million USD | 6.34% |
| 2008 FY | -11.11 Million USD | -6.74% |
| 2007 FY | -10.41 Million USD | -30.56% |
| 2007 Q1 | -1.6 Million USD | 22.22% |
| 2007 Q2 | -1.99 Million USD | -24.42% |
| 2007 Q3 | -2.67 Million USD | -34.04% |
| 2007 Q4 | -5.86 Million USD | -119.24% |
| 2006 Q4 | -2.06 Million USD | 2.05% |
| 2006 Q3 | -2.1 Million USD | -16.66% |
| 2006 Q2 | -1.8 Million USD | 5.77% |
| 2006 Q1 | -1.91 Million USD | -1147.86% |
| 2006 FY | -7.97 Million USD | -187.95% |
| 2005 Q2 | -629.45 Thousand USD | 34.52% |
| 2005 Q3 | -1.28 Million USD | -104.76% |
| 2005 FY | -2.76 Million USD | 41.36% |
| 2005 Q4 | 182.92 Thousand USD | 114.19% |
| 2005 Q1 | -961.36 Thousand USD | -67.3% |
| 2004 FY | -4.72 Million USD | -1306.04% |
| 2004 Q2 | -1.46 Million USD | -33.38% |
| 2004 Q4 | -574.62 Thousand USD | 60.48% |
| 2004 Q1 | -1.09 Million USD | -968.03% |
| 2004 Q3 | -1.45 Million USD | 0.88% |
| 2003 Q2 | -450.62 Thousand USD | -165.54% |
| 2003 Q3 | -530.39 Thousand USD | -17.7% |
| 2003 Q4 | -102.98 Thousand USD | 80.58% |
| 2003 Q1 | 687.58 Thousand USD | 318.1% |
| 2003 FY | -335.9 Thousand USD | 61.9% |
| 2002 FY | -881.57 Thousand USD | 30.04% |
| 2002 Q4 | -315.25 Thousand USD | 37.28% |
| 2002 Q1 | -488.88 Thousand USD | -50.61% |
| 2002 Q2 | -853.23 Thousand USD | -74.53% |
| 2002 Q3 | -502.67 Thousand USD | 41.09% |
| 2001 Q1 | -439.78 Thousand USD | -61.18% |
| 2001 FY | -1.26 Million USD | -410.72% |
| 2001 Q4 | -324.59 Thousand USD | -52.61% |
| 2001 Q3 | -212.69 Thousand USD | 28.63% |
| 2001 Q2 | -298.01 Thousand USD | 32.24% |
| 2000 Q4 | -272.84 Thousand USD | -4.75% |
| 2000 Q3 | -260.48 Thousand USD | 0.0% |
| 2000 Q1 | -8106.49 USD | -113.13% |
| 2000 FY | -246.73 Thousand USD | -717.61% |
| 1999 FY | 39.94 Thousand USD | 687.31% |
| 1999 Q4 | 61.72 Thousand USD | 1422.72% |
| 1999 Q1 | -7332.45 USD | 0.0% |
| 1999 Q3 | -4666.29 USD | 52.56% |
| 1999 Q2 | -9836.62 USD | -34.15% |
| 1998 FY | -6802.08 USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| American Bio Medica Corporation | -1.24 Million USD | -523.733% |
| Arrayit Corporation | -3.62 Million USD | -113.85% |
| Atlantic International Corp. | -5.73 Million USD | -35.137% |
| Biocept, Inc. | -31.98 Million USD | 75.779% |
| Bioqual, Inc. | -19.63 Thousand USD | -39347.81% |
| CardioGenics Holdings Inc | -772.14 Thousand USD | -903.282% |
| DermTech, Inc. | -103.73 Million USD | 92.532% |
| Global WholeHealth Partners Corporation | - USD | Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.48 Billion USD | 100.311% |
| HTG Molecular Diagnostics, Inc. | -20.82 Million USD | 62.809% |
| iMD Companies, Inc. | -175.44 Thousand USD | -4315.467% |
| IDenta Corp. | -1499.00 USD | -516695.264% |
| Interpace Biosciences, Inc. | 2.8 Million USD | 376.275% |
| Integrative Health Technologies, Inc. | 38.69 Thousand USD | 20122.644% |
| InVitro International | -25.33 Thousand USD | -30472.481% |
| Lumos Diagnostics Holdings Limited | -7.12 Million USD | -8.772% |
| Many Bright Ideas Technologies Inc. | -58.11 Thousand USD | -13230.742% |
| Medical Imaging Corp. | -819.48 Thousand USD | -845.326% |
| NovelStem International Corp. | -3.52 Million USD | -119.716% |
| Optigenex Inc. | 1.39 Million USD | 656.986% |
| PharmChem, Inc. | 973.14 Thousand USD | 896.052% |
| Proteome Sciences plc | -1.62 Million USD | -377.9% |
| Response Genetics, Inc | -21.37 Million USD | 63.761% |
| Rennova Health, Inc. | -1.4 Million USD | -449.597% |
| RushNet, Inc. | -684.7 Thousand USD | -1031.401% |
| ScreenPro Security Inc. | -2.59 Million USD | -198.823% |
| Stella Diagnostics Inc. | -11.42 Million USD | 32.206% |
| Todos Medical Ltd. | -9.74 Million USD | 20.53% |